Literature DB >> 10706700

The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine.

K Kusakabe1, K Q Xin, H Katoh, K Sumino, E Hagiwara, S Kawamoto, K Okuda, Y Miyagi, I Aoki, K Nishioka, D Klinman, K Okuda.   

Abstract

The mechanism of immune activation induced by a plasmid-encoding GM-CSF (pGM-CSF), administered in combination with a DNA vaccine encoding the envelope of HIV, was studied. Injecting pGM-CSF i.m. into mice 3 days before DNA vaccination primarily induced a Th2 response. Simultaneous administration of the DNA vaccine plus pGM-CSF activated both a Th1 and a Th2 response. When the plasmid was injected 3 days after DNA vaccination, enhancement of Th1 immunity predominated. These results suggest that the timing of cytokine expression determines the phenotype of the resultant Th response. After 3 days of pGM-CSF injection, the increased percentages of CD11c+, CD8+ cells were observed in the regional lymph nodes. In addition, many infiltrated cells, including S-100 protein-positive cells, were found in the pGM-CSF-injected tissue. The importance of these S-100+ cells or both CD8+ and CD11c+ cells, especially that of dendritic cells (DCs), was also studied. DCs derived from bone marrow and cultured in RPMI 1640 medium containing IL-4 and GM-CSF were incubated with DNA vaccine and then transferred into naive mice. Mice receiving DCs showed strong HIV-1-specific Th2 immune responses. Our results suggest that DCs play important roles in the activation or modification of the Th2-type immune response induced by DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706700     DOI: 10.4049/jimmunol.164.6.3102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Sm-p80): adjuvant effects of granulocyte-macrophage colony-stimulating factor and interleukin-4.

Authors:  Afzal A Siddiqui; Troy Phillips; Hugues Charest; Ron B Podesta; Martha L Quinlin; Justin R Pinkston; Jenny D Lloyd; Michelle Paz; Rachael M Villalovos; Janet Pompa
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

4.  Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Authors:  Ruijiang Song; Shuqin Liu; Kam W Leong
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

5.  Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Authors:  Noshin Kathuria; Kimberly A Kraynyak; Diane Carnathan; Michael Betts; David B Weiner; Michele A Kutzler
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 6.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

7.  Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice.

Authors:  Anne C Moore; Wing-pui Kong; Bimal K Chakrabarti; Gary J Nabel
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.

Authors:  Mariana O Diniz; Marcio O Lasaro; Hildegund C Ertl; Luís C S Ferreira
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

9.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

10.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.